Articles from CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Progress in Establishing Transformative Therapeutic Pipeline
Company has been exploring multiple acquisition and licensing opportunities, with the goal of securing first transaction by year-end$17.2 million cash position provides financial strength to support strategic execution and planned operations
By CNS Pharmaceuticals, Inc. · Via ACCESS Newswire · November 16, 2026
CNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of Growth
Chief Business Officer, Dylan Wenke, Participates in Virtual Investor "What This Means" Segment
By CNS Pharmaceuticals, Inc. · Via ACCESS Newswire · September 1, 2026
CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference
Video webcast now available here
By CNS Pharmaceuticals, Inc. · Via ACCESS Newswire · August 27, 2026
CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation
Company reports approximately $20.0 million cash position and extended operating runway following oversubscribed $22.5 million financing, as it advances its pivot toward a diversified, high-value pipeline
By CNS Pharmaceuticals, Inc. · Via ACCESS Newswire · August 12, 2026